Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Cash & Equivalents (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Cash & Equivalents for 16 consecutive years, with $30.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 50.26% to $30.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.6 million through Dec 2025, down 50.26% year-over-year, with the annual reading at $30.6 million for FY2025, 50.26% down from the prior year.
  • Cash & Equivalents hit $30.6 million in Q4 2025 for Perspective Therapeutics, down from $174.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $252.0 million in Q2 2024 to a low of $9.2 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $81.0 million across 5 years, with a median of $59.6 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: surged 3079.9% in 2021 and later tumbled 69.22% in 2022.
  • Year by year, Cash & Equivalents stood at $60.4 million in 2021, then plummeted by 65.22% to $21.0 million in 2022, then plummeted by 55.99% to $9.2 million in 2023, then surged by 566.59% to $61.6 million in 2024, then crashed by 50.26% to $30.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for CATX at $30.6 million in Q4 2025, $174.1 million in Q3 2025, and $191.6 million in Q2 2025.